1
|
He X, Hu Z, Dev H, Romano DJ, Sharbatdaran A, Raza SI, Wang SJ, Teichman K, Shih G, Chevalier JM, Shimonov D, Blumenfeld JD, Goel A, Sabuncu MR, Prince MR. Test Retest Reproducibility of Organ Volume Measurements in ADPKD Using 3D Multimodality Deep Learning. Acad Radiol 2024; 31:889-899. [PMID: 37798206 PMCID: PMC10957335 DOI: 10.1016/j.acra.2023.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Revised: 08/28/2023] [Accepted: 09/05/2023] [Indexed: 10/07/2023]
Abstract
RATIONALE AND OBJECTIVES Following autosomal dominant polycystic kidney disease (ADPKD) progression by measuring organ volumes requires low measurement variability. The objective of this study is to reduce organ volume measurement variability on MRI of ADPKD patients by utilizing all pulse sequences to obtain multiple measurements which allows outlier analysis to find errors and averaging to reduce variability. MATERIALS AND METHODS In order to make measurements on multiple pulse sequences practical, a 3D multi-modality multi-class segmentation model based on nnU-net was trained/validated using T1, T2, SSFP, DWI and CT from 413 subjects. Reproducibility was assessed with test-re-test methodology on ADPKD subjects (n = 19) scanned twice within a 3-week interval correcting outliers and averaging the measurements across all sequences. Absolute percent differences in organ volumes were compared to paired students t-test. RESULTS Dice similarlity coefficient > 97%, Jaccard Index > 0.94, mean surface distance < 1 mm and mean Hausdorff Distance < 2 cm for all three organs and all five sequences were found on internal (n = 25), external (n = 37) and test-re-test reproducibility assessment (38 scans in 19 subjects). When averaging volumes measured from five MRI sequences, the model automatically segmented kidneys with test-re-test reproducibility (percent absolute difference between exam 1 and exam 2) of 1.3% which was better than all five expert observers. It reliably stratified ADPKD into Mayo Imaging Classification (area under the curve=100%) compared to radiologist. CONCLUSION 3D deep learning measures organ volumes on five MRI sequences leveraging the power of outlier analysis and averaging to achieve 1.3% total kidney test-re-test reproducibility.
Collapse
Affiliation(s)
- Xinzi He
- School of Electrical and Computer Engineering, Cornell University and Cornell Tech, New York, New York (X.H., R.S.); Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Zhongxiu Hu
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Hreedi Dev
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Dominick J Romano
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Arman Sharbatdaran
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Syed I Raza
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Sophie J Wang
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Kurt Teichman
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - George Shih
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - James M Chevalier
- Department of Medicine, Weill Cornell Medicine, New York, New York (J.M.C., D.S., J.D.B.); The Rogosin Institute, New York, New York (J.M.C., D.S., J.D.B.)
| | - Daniil Shimonov
- Department of Medicine, Weill Cornell Medicine, New York, New York (J.M.C., D.S., J.D.B.); The Rogosin Institute, New York, New York (J.M.C., D.S., J.D.B.)
| | - Jon D Blumenfeld
- Department of Medicine, Weill Cornell Medicine, New York, New York (J.M.C., D.S., J.D.B.); The Rogosin Institute, New York, New York (J.M.C., D.S., J.D.B.)
| | - Akshay Goel
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Mert R Sabuncu
- School of Electrical and Computer Engineering, Cornell University and Cornell Tech, New York, New York (X.H., R.S.); Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.)
| | - Martin R Prince
- Department of Radiology, Weill Cornell Medicine, New York, New York (X.H., Z.H., H.D., D.J.R., A.S., S.I.R., S.J.W., K.T., G.S., A.G., R.S., M.R.P.); Columbia University Vagelos College of Physicians and Surgeons, New York, New York (M.R.P.).
| |
Collapse
|
2
|
Dev H, Zhu C, Sharbatdaran A, Raza SI, Wang SJ, Romano DJ, Goel A, Teichman K, Moghadam MC, Shih G, Blumenfeld JD, Shimonov D, Chevalier JM, Prince MR. Effect of Averaging Measurements From Multiple MRI Pulse Sequences on Kidney Volume Reproducibility in Autosomal Dominant Polycystic Kidney Disease. J Magn Reson Imaging 2023; 58:1153-1160. [PMID: 36645114 PMCID: PMC10947493 DOI: 10.1002/jmri.28593] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 12/27/2022] [Accepted: 12/28/2022] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Total kidney volume (TKV) is an important biomarker for assessing kidney function, especially for autosomal dominant polycystic kidney disease (ADPKD). However, TKV measurements from a single MRI pulse sequence have limited reproducibility, ± ~5%, similar to ADPKD annual kidney growth rates. PURPOSE To improve TKV measurement reproducibility on MRI by extending artificial intelligence algorithms to automatically segment kidneys on T1-weighted, T2-weighted, and steady state free precession (SSFP) sequences in axial and coronal planes and averaging measurements. STUDY TYPE Retrospective training, prospective testing. SUBJECTS Three hundred ninety-seven patients (356 with ADPKD, 41 without), 75% for training and 25% for validation, 40 ADPKD patients for testing and 17 ADPKD patients for assessing reproducibility. FIELD STRENGTH/SEQUENCE T2-weighted single-shot fast spin echo (T2), SSFP, and T1-weighted 3D spoiled gradient echo (T1) at 1.5 and 3T. ASSESSMENT 2D U-net segmentation algorithm was trained on images from all sequences. Five observers independently measured each kidney volume manually on axial T2 and using model-assisted segmentations on all sequences and image plane orientations for two MRI exams in two sessions separated by 1-3 weeks to assess reproducibility. Manual and model-assisted segmentation times were recorded. STATISTICAL TESTS Bland-Altman, Schapiro-Wilk (normality assessment), Pearson's chi-squared (categorical variables); Dice similarity coefficient, interclass correlation coefficient, and concordance correlation coefficient for analyzing TKV reproducibility. P-value < 0.05 was considered statistically significant. RESULTS In 17 ADPKD subjects, model-assisted segmentations of axial T2 images were significantly faster than manual segmentations (2:49 minute vs. 11:34 minute), with no significant absolute percent difference in TKV (5.9% vs. 5.3%, P = 0.88) between scans 1 and 2. Absolute percent differences between the two scans for model-assisted segmentations on other sequences were 5.5% (axial T1), 4.5% (axial SSFP), 4.1% (coronal SSFP), and 3.2% (coronal T2). Averaging measurements from all five model-assisted segmentations significantly reduced absolute percent difference to 2.5%, further improving to 2.1% after excluding an outlier. DATA CONCLUSION Measuring TKV on multiple MRI pulse sequences in coronal and axial planes is practical with deep learning model-assisted segmentations and can improve TKV measurement reproducibility more than 2-fold in ADPKD. EVIDENCE LEVEL 2 TECHNICAL EFFICACY: Stage 1.
Collapse
Affiliation(s)
- Hreedi Dev
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Chenglin Zhu
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Arman Sharbatdaran
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Syed I. Raza
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Sophie J. Wang
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Dominick J. Romano
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Akshay Goel
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Kurt Teichman
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Mina C. Moghadam
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - George Shih
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
| | - Jon D. Blumenfeld
- Department of Medicine, Weill Cornell Medicine, New York City, New York, USA
- The Rogosin Institute, New York City, New York, USA
| | - Daniil Shimonov
- Department of Medicine, Weill Cornell Medicine, New York City, New York, USA
- The Rogosin Institute, New York City, New York, USA
| | - James M. Chevalier
- Department of Medicine, Weill Cornell Medicine, New York City, New York, USA
- The Rogosin Institute, New York City, New York, USA
| | - Martin R. Prince
- Department of Radiology, Weill Cornell Medicine, New York City, New York, USA
- Columbia College of Physicians and Surgeons, New York City, New York, USA
| |
Collapse
|
3
|
Sharbatdaran A, Romano D, Teichman K, Dev H, Raza SI, Goel A, Moghadam MC, Blumenfeld JD, Chevalier JM, Shimonov D, Shih G, Wang Y, Prince MR. Deep Learning Automation of Kidney, Liver, and Spleen Segmentation for Organ Volume Measurements in Autosomal Dominant Polycystic Kidney Disease. Tomography 2022; 8:1804-1819. [PMID: 35894017 PMCID: PMC9326744 DOI: 10.3390/tomography8040152] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 07/01/2022] [Accepted: 07/08/2022] [Indexed: 12/02/2022] Open
Abstract
Organ volume measurements are a key metric for managing ADPKD (the most common inherited renal disease). However, measuring organ volumes is tedious and involves manually contouring organ outlines on multiple cross-sectional MRI or CT images. The automation of kidney contouring using deep learning has been proposed, as it has small errors compared to manual contouring. Here, a deployed open-source deep learning ADPKD kidney segmentation pipeline is extended to also measure liver and spleen volumes, which are also important. This 2D U-net deep learning approach was developed with radiologist labeled T2-weighted images from 215 ADPKD subjects (70% training = 151, 30% validation = 64). Additional ADPKD subjects were utilized for prospective (n = 30) and external (n = 30) validations for a total of 275 subjects. Image cropping previously optimized for kidneys was included in training but removed for the validation and inference to accommodate the liver which is closer to the image border. An effective algorithm was developed to adjudicate overlap voxels that are labeled as more than one organ. Left kidney, right kidney, liver and spleen labels had average errors of 3%, 7%, 3%, and 1%, respectively, on external validation and 5%, 6%, 5%, and 1% on prospective validation. Dice scores also showed that the deep learning model was close to the radiologist contouring, measuring 0.98, 0.96, 0.97 and 0.96 on external validation and 0.96, 0.96, 0.96 and 0.95 on prospective validation for left kidney, right kidney, liver and spleen, respectively. The time required for manual correction of deep learning segmentation errors was only 19:17 min compared to 33:04 min for manual segmentations, a 42% time saving (p = 0.004). Standard deviation of model assisted segmentations was reduced to 7, 5, 11, 5 mL for right kidney, left kidney, liver and spleen respectively from 14, 10, 55 and 14 mL for manual segmentations. Thus, deep learning reduces the radiologist time required to perform multiorgan segmentations in ADPKD and reduces measurement variability.
Collapse
Affiliation(s)
- Arman Sharbatdaran
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Dominick Romano
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Kurt Teichman
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Hreedi Dev
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Syed I. Raza
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Akshay Goel
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Mina C. Moghadam
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Jon D. Blumenfeld
- The Rogosin Institute and Department of Medicine Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (J.D.B.); (J.M.C.); (D.S.)
| | - James M. Chevalier
- The Rogosin Institute and Department of Medicine Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (J.D.B.); (J.M.C.); (D.S.)
| | - Daniil Shimonov
- The Rogosin Institute and Department of Medicine Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (J.D.B.); (J.M.C.); (D.S.)
| | - George Shih
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
| | - Yi Wang
- Departments of Radiology at Weill Cornell Medicine and Biomedical Engineering, Cornell University, New York, NY 10065, USA;
| | - Martin R. Prince
- Department of Radiology, Weill Cornell Medicine, Cornell University, New York, NY 10065, USA; (A.S.); (D.R.); (K.T.); (H.D.); (S.I.R.); (A.G.); (M.C.M.); (G.S.)
- Columbia College of Physicians and Surgeons, Cornell University, New York, NY 10027, USA
| |
Collapse
|
4
|
Riyahi S, Dev H, Behzadi A, Kim J, Attari H, Raza SI, Margolis DJ, Jonisch A, Megahed A, Bamashmos A, Elfatairy K, Prince MR. Pulmonary Embolism in Hospitalized Patients with COVID-19: A Multicenter Study. Radiology 2021; 301:E426-E433. [PMID: 34254850 PMCID: PMC8294351 DOI: 10.1148/radiol.2021210777] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background Pulmonary embolism (PE) commonly complicates SARS-CoV-2 infection, but incidence and mortality reported in single-center studies, along with risk factors, vary. Purpose To determine the incidence of PE in patients with COVID-19 and its associations with clinical and laboratory parameters. Materials and Methods In this HIPAA-compliant study, electronic medical records were searched retrospectively for demographic, clinical, and laboratory data and outcomes among patients with COVID-19 admitted at four hospitals from March through June 2020. PE found at CT pulmonary angiography and perfusion scintigraphy was correlated with clinical and laboratory parameters. The d-dimer level was used to predict PE, and the obtained threshold was externally validated among 85 hospitalized patients with COVID-19 at a fifth hospital. The association between right-sided heart strain and embolic burden was evaluated in patients with PE undergoing echocardiography. Results A total of 413 patients with COVID-19 (mean age, 60 years ± 16 [standard deviation]; age range, 20–98 years; 230 men) were evaluated. PE was diagnosed in 102 (25%; 95% CI: 21, 29) of 413 hospitalized patients with COVID-19 who underwent CT pulmonary angiography or perfusion scintigraphy. PE was observed in 21 (29%; 95% CI: 19, 41) of 73 patients in the intensive care unit (ICU) versus 81 (24%; 95% CI: 20, 29) of 340 patients who were not in the ICU (P = .37). PE was associated with male sex (odds ratio [OR], 1.74; 95% CI: 1.1, 2.8; P = .02); smoking (OR, 1.86; 95% CI: 1.0, 3.4; P = .04); and increased d-dimer (P < .001), lactate dehydrogenase (P < .001), ferritin (P = .001), and interleukin-6 (P = .02) levels. Mortality in hospitalized patients was similar between patients with PE and those without PE (14% [13 of 102]; 95% CI: 8, 22] vs 13% [40 of 311]; 95% CI: 9, 17; P = .98), suggesting that diagnosis and treatment of PE were not associated with excess mortality. The d-dimer levels greater than 1600 ng/mL [8.761 nmol/L] helped predict PE with 100% sensitivity and 62% specificity in an external validation cohort. Embolic burden was higher in patients with right-sided heart strain among the patients with PE undergoing echocardiography (P = .03). Conclusion Pulmonary embolism (PE) incidence was 25% in patients hospitalized with COVID-19 suspected of having PE. A d-dimer level greater than 1600 ng/mL [8.761 nmol/L] was sensitive for identification of patients who needed CT pulmonary angiography. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Ketai in this issue.
Collapse
Affiliation(s)
- Sadjad Riyahi
- From the Departments of Radiology at Weill Cornell Medicine
| | - Hreedi Dev
- From the Departments of Radiology at Weill Cornell Medicine
| | | | - Jinhye Kim
- From the Departments of Radiology at Weill Cornell Medicine
| | - Hanieh Attari
- From the Departments of Radiology at Weill Cornell Medicine
| | - Syed I Raza
- From the Departments of Radiology at Weill Cornell Medicine
| | | | - Ari Jonisch
- From the Departments of Radiology at Weill Cornell Medicine
| | - Ayah Megahed
- Bridgeport Hospital, Yale New Haven Health System, CT
| | | | | | - Martin R Prince
- From the Departments of Radiology at Weill Cornell Medicine.,Columbia College of Physicians and Surgeons, NY
| |
Collapse
|
5
|
Farmer RE, Beard I, Raza SI, Gollop ND, Patel N, Tebboth A, McGovern AP, Kanumilli N, Ternouth A. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD. Clin Ther 2021; 43:320-335. [PMID: 33581878 DOI: 10.1016/j.clinthera.2020.12.015] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 12/02/2020] [Accepted: 12/20/2020] [Indexed: 01/02/2023]
Abstract
PURPOSE Some classes of glucose-lowering medications, including sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1-receptor agonists (GLP1-RAs) have cardio-protective benefit, but it is unclear whether this influences prescribing in the United Kingdom (UK). This study aims to describe class-level prescribing in adults with type 2 diabetes mellitus (T2DM) by cardiovascular disease (CVD) history using the Clinical Practice Research Datalink (CPRD). METHODS Four cross-sections of people with T2DM aged 18-90 and registered with their general practice for >1 year on 1st January 2017 (n = 166,012), 1st January 2018 (n = 155,290), 1st January 2019 (n = 152,602) and 31st December 2019 (n = 143,373) were identified. Age-standardised proportions for class use through time were calculated separately in those with and without CVD history and by total number of medications prescribed (one, two, three, four+). An analysis by UK country was also performed. FINDINGS Around 31% of patients had CVD history at each cross-section. Metformin was the most common treatment (>70% of those with and without CVD had prescriptions across all treatment lines). Overall use of SGLT2is and GLP1-RAs was low, with slightly less use in patients with CVD (SGLT2i: 9.8% and 13.8% in those with and without CVD respectively; GLP1-RA: 4.3% and 4.9%, December 2019). Use of SGLT2is as part of dual therapy was low but rose throughout the study. In January 2017, estimated use was 8.0% (95% CI 6.9-9.1%) and 8.9% (8.6-9.3%) in those with and without CVD. By December 2019 this reached 18.3% (17.0-19.5%) and 21.2% (20.6-21.7%) for those with and without CVD respectively. SGLT2i use as triple therapy increased: 22.7% (21.0-24.4%) and 25.9% (25.2-26.6%) in January 2017 to 41.3% (39.5-43.0%) and 45.5% (44.7-46.3%) in December 2019. GLP1-RA use also increased, but observed usage remained lower than SGLT2 inhibitors. Insulin use remained stable throughout, with higher use observed in those with CVD (16% vs 9.7% Dec 2019). Time trends in England, Wales, Scotland and Northern Ireland were similar, although class prevalence varied. IMPLICATIONS Although use of SGLT2is and GLP1-RAs has increased, overall usage remains low with slightly lower use in those with CVD history, suggesting there is opportunity to optimise use of these medicines in T2DM patients to manage CVD risk. Insulin use was substantially more prevalent in those with CVD despite no evidence of CVD benefit. Further investigation of factors influencing this finding may highlight strategies to improve patient access to the most appropriate treatments, including those with evidence of cardiovascular benefit.
Collapse
Affiliation(s)
- Ruth E Farmer
- Boehringer Ingelheim Ltd, Bracknell, United Kingdom.
| | - Ivan Beard
- Boehringer Ingelheim Ltd, Bracknell, United Kingdom
| | - Syed I Raza
- Boehringer Ingelheim Ltd, Bracknell, United Kingdom
| | | | - Niraj Patel
- Boehringer Ingelheim Ltd, Bracknell, United Kingdom
| | | | - Andrew P McGovern
- University of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, United Kingdom
| | | | | |
Collapse
|
6
|
Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK. Diabetes Ther 2020; 11:2041-2055. [PMID: 32700188 PMCID: PMC7434815 DOI: 10.1007/s13300-020-00883-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Indexed: 01/17/2023] Open
Abstract
INTRODUCTION International guidelines recommend treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist for treatment intensification in type 2 diabetes mellitus (T2DM) patients with progression on metformin. In the randomised, controlled, Peptide Innovation for Early Diabetes Treatment (PIONEER) 2 trial, the SGLT-2 inhibitor empagliflozin was compared with the GLP-1 receptor agonist oral semaglutide, in addition to metformin. The aim of the current study was to assess the long-term cost-effectiveness of empagliflozin 25 mg versus oral semaglutide 14 mg, in addition to metformin, for T2DM patients in the UK. METHODS Analyses were conducted from the UK healthcare payer perspective, using the IQVIA Core Diabetes model, with a time horizon of 50 years. Patients received either empagliflozin or oral semaglutide, in addition to metformin, until Hba1c threshold of 7.5% (58 mmol/mol) was exceeded, following which treatment intensification with insulin glargine in addition to empagliflozin or oral semaglutide plus metformin was assumed. Baseline cohort characteristics and 52-week treatment effects were derived from the PIONEER 2 trial. Treatment effects of empagliflozin and GLP-1 receptor agonists on hospitalisation for heart failure (hHF) were based on the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) real-world study. Utilities, treatment costs and costs of diabetes-related complications were obtained from published sources. RESULTS Direct costs for empagliflozin plus metformin were considerably lower than those for oral semaglutide plus metformin (by more than GBP 6000). Compared with oral semaglutide plus metformin, empagliflozin plus metformin was a cost-effective treatment for T2DM patients in all scenarios tested. Probabilistic sensitivity analysis showed cost-effectiveness in > 95% of the iterations using a threshold of 20,000 GBP/QALY. CONCLUSION Empagliflozin 25 mg is a cost-effective treatment option versus oral semaglutide 14 mg, when used in addition to metformin, for the treatment of T2DM patients in the UK.
Collapse
Affiliation(s)
- Mafalda Ramos
- Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal
| | - Michael H Cummings
- Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK
| | | | - Syed I Raza
- Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK
| | | | - Mark Lamotte
- Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium.
| |
Collapse
|
7
|
Spencer S, Köstel Bal S, Egner W, Lango Allen H, Raza SI, Ma CA, Gürel M, Zhang Y, Sun G, Sabroe RA, Greene D, Rae W, Shahin T, Kania K, Ardy RC, Thian M, Staples E, Pecchia-Bekkum A, Worrall WPM, Stephens J, Brown M, Tuna S, York M, Shackley F, Kerrin D, Sargur R, Condliffe A, Tipu HN, Kuehn HS, Rosenzweig SD, Turro E, Tavaré S, Thrasher AJ, Jodrell DI, Smith KGC, Boztug K, Milner JD, Thaventhiran JED. Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med 2019; 216:1986-1998. [PMID: 31235509 PMCID: PMC6719421 DOI: 10.1084/jem.20190344] [Citation(s) in RCA: 124] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 04/20/2019] [Accepted: 06/06/2019] [Indexed: 12/14/2022] Open
Abstract
IL-6 excess is central to the pathogenesis of multiple inflammatory conditions and is targeted in clinical practice by immunotherapy that blocks the IL-6 receptor encoded by IL6R We describe two patients with homozygous mutations in IL6R who presented with recurrent infections, abnormal acute-phase responses, elevated IgE, eczema, and eosinophilia. This study identifies a novel primary immunodeficiency, clarifying the contribution of IL-6 to the phenotype of patients with mutations in IL6ST, STAT3, and ZNF341, genes encoding different components of the IL-6 signaling pathway, and alerts us to the potential toxicity of drugs targeting the IL-6R.
Collapse
Affiliation(s)
- Sarah Spencer
- Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Sevgi Köstel Bal
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
- CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
| | - William Egner
- Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
- Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Hana Lango Allen
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
| | - Syed I Raza
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
| | - Chi A Ma
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
| | - Meltem Gürel
- Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UK
| | - Yuan Zhang
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
| | - Guangping Sun
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
| | - Ruth A Sabroe
- Department of Dermatology, Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
| | - Daniel Greene
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
- Medical Research Council Biostatistics Unit, Cambridge Biomedical Campus, Cambridge, UK
| | - William Rae
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Tala Shahin
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
- CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
| | - Katarzyna Kania
- Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UK
| | - Rico Chandra Ardy
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
- CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
| | - Marini Thian
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
- CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
- St. Anna Kinderspital and Children's Cancer Research Institute, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
| | - Emily Staples
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Annika Pecchia-Bekkum
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - William P M Worrall
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Jonathan Stephens
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
- National Health Service Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Matthew Brown
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
- National Health Service Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Salih Tuna
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
- National Health Service Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Melanie York
- Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
- Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Fiona Shackley
- Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
- Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Diarmuid Kerrin
- Barnsley Hospitals National Health Service Foundation Trust, Barnsley, UK
| | - Ravishankar Sargur
- Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
- Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Alison Condliffe
- Sheffield Teaching Hospitals National Health Service Trust, Sheffield, UK
- Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | - Hamid Nawaz Tipu
- Immunology Department, Armed Forces Institute of Pathology, Rawalpindi, Pakistan
| | - Hye Sun Kuehn
- Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Sergio D Rosenzweig
- Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
| | - Ernest Turro
- Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK
- Medical Research Council Biostatistics Unit, Cambridge Biomedical Campus, Cambridge, UK
- National Health Service Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Simon Tavaré
- Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UK
- Herbert and Florence Irving Institute for Cancer Dynamics, Columbia University, New York, NY
- New York Genome Center, New York, NY
| | - Adrian J Thrasher
- Molecular and Cellular Immunology Section, University College London Great Ormond Street Institute of Child Health, Great Ormond Street Hospital National Health Service Trust, London, UK
| | - Duncan Ian Jodrell
- Department of Oncology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Kenneth G C Smith
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
| | - Kaan Boztug
- Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria
- CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
- St. Anna Kinderspital and Children's Cancer Research Institute, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria
- Vienna Center for Rare and Undiagnosed Diseases, Vienna, Austria
| | - Joshua D Milner
- Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
| | - James E D Thaventhiran
- Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK
- Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
- Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, Cambridge, UK
| |
Collapse
|
8
|
Mehmood S, Raza SI, Van Bokhoven H, Ahmad W. Autosomal recessive transmission of a rare HOXC13 variant causes pure hair and nail ectodermal dysplasia. Clin Exp Dermatol 2017; 42:585-589. [PMID: 28543635 DOI: 10.1111/ced.13115] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/16/2016] [Indexed: 11/26/2022]
Affiliation(s)
- S Mehmood
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
| | - S I Raza
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
| | - H Van Bokhoven
- Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
| | - W Ahmad
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
| |
Collapse
|
9
|
Rehman AU, Santos-Cortez RLP, Morell RJ, Drummond MC, Ito T, Lee K, Khan AA, Basra MAR, Wasif N, Ayub M, Ali RA, Raza SI, Nickerson DA, Shendure J, Bamshad M, Riazuddin S, Billington N, Khan SN, Friedman PL, Griffith AJ, Ahmad W, Riazuddin S, Leal SM, Friedman TB. Mutations in TBC1D24, a gene associated with epilepsy, also cause nonsyndromic deafness DFNB86. Am J Hum Genet 2014; 94:144-52. [PMID: 24387994 DOI: 10.1016/j.ajhg.2013.12.004] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Accepted: 12/06/2013] [Indexed: 01/12/2023] Open
Abstract
Inherited deafness is clinically and genetically heterogeneous. We recently mapped DFNB86, a locus associated with nonsyndromic deafness, to chromosome 16p. In this study, whole-exome sequencing was performed with genomic DNA from affected individuals from three large consanguineous families in which markers linked to DFNB86 segregate with profound deafness. Analyses of these data revealed homozygous mutation c.208G>T (p.Asp70Tyr) or c.878G>C (p.Arg293Pro) in TBC1D24 as the underlying cause of deafness in the three families. Sanger sequence analysis of TBC1D24 in an additional large family in which deafness segregates with DFNB86 identified the c.208G>T (p.Asp70Tyr) substitution. These mutations affect TBC1D24 amino acid residues that are conserved in orthologs ranging from fruit fly to human. Neither variant was observed in databases of single-nucleotide variants or in 634 chromosomes from ethnically matched control subjects. TBC1D24 in the mouse inner ear was immunolocalized predominantly to spiral ganglion neurons, indicating that DFNB86 deafness might be an auditory neuropathy spectrum disorder. Previously, six recessive mutations in TBC1D24 were reported to cause seizures (hearing loss was not reported) ranging in severity from epilepsy with otherwise normal development to epileptic encephalopathy resulting in childhood death. Two of our four families in which deafness segregates with mutant alleles of TBC1D24 were available for neurological examination. Cosegregation of epilepsy and deafness was not observed in these two families. Although the causal relationship between genotype and phenotype is not presently understood, our findings, combined with published data, indicate that recessive alleles of TBC1D24 can cause either epilepsy or nonsyndromic deafness.
Collapse
Affiliation(s)
- Atteeq U Rehman
- Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA
| | - Regie Lyn P Santos-Cortez
- Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Robert J Morell
- Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA
| | - Meghan C Drummond
- Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA
| | - Taku Ito
- Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA
| | - Kwanghyuk Lee
- Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
| | - Asma A Khan
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 54500, Pakistan
| | - Muhammad Asim R Basra
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 54500, Pakistan
| | - Naveed Wasif
- Center for Research in Molecular Medicine, Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan
| | - Muhammad Ayub
- Institute of Biochemistry, University of Baluchistan, Quetta 87300, Pakistan
| | - Rana A Ali
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 54500, Pakistan
| | - Syed I Raza
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad 45320, Pakistan
| | - Deborah A Nickerson
- Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
| | - Jay Shendure
- Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
| | - Michael Bamshad
- Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
| | - Saima Riazuddin
- Division of Pediatric Otolaryngology - Head and Neck Surgery, Cincinnati Children's Research Foundation, Cincinnati, OH 45229 USA; Department of Otolaryngology - Head and Neck Surgery, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
| | - Neil Billington
- Laboratory of Molecular Physiology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Shaheen N Khan
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 54500, Pakistan
| | | | - Andrew J Griffith
- Otolaryngology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA
| | - Wasim Ahmad
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad 45320, Pakistan
| | - Sheikh Riazuddin
- Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 54500, Pakistan; Allama Iqbal Medical College and Jinnah Hospital Complex, University of Health Sciences, Lahore 54550, Pakistan
| | - Suzanne M Leal
- Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
| | - Thomas B Friedman
- Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Rockville, MD 20850, USA.
| |
Collapse
|
10
|
Tariq M, Ayub M, Jelani M, Basit S, Naz G, Wasif N, Raza SI, Naveed AK, ullah Khan S, Azeem Z, Yasinzai M, Wali A, Ali G, Chishti MS, Ahmad W. Mutations in the P2RY5 gene underlie autosomal recessive hypotrichosis in 13 Pakistani families. Br J Dermatol 2009; 160:1006-10. [PMID: 19292720 DOI: 10.1111/j.1365-2133.2009.09046.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Autosomal recessive hypotrichosis is a rare genetic irreversible hair loss characterized by sparse scalp hair, sparse to absent eyebrows and eyelashes, and sparse axillary and body hair. Affected male individuals have normal beard hair. OBJECTIVES To search for pathogenic mutations in the human P2RY5 gene in Pakistani families with autosomal recessive hereditary hypotrichosis. METHODS In the present report, 16 unrelated consanguineous Pakistani families having multiple affected individuals with autosomal recessive hypotrichosis were investigated. Linkage in these families was searched by genotyping microsatellite markers linked to autosomal recessive hypotrichosis loci LAH1, LAH2 and LAH3. Thirteen of the families showed linkage to the LAH3 locus on chromosome 13q14.11-q21.32. These families were then subjected to direct sequencing of the P2RY5 gene, which encodes a G protein-coupled receptor. RESULTS Sequence analysis of the P2RY5 gene revealed two novel missense mutations (c.742A>T; p.N248Y and c.830C>T; p.L277P) in three families. Five previously described mutations including three missense (c.188A>T; p.D63V, c.436G>A; p.G146R, c.562A>T; p.I188F), one insertion (c.69insCATG; p.24insHfsX52) and one complex deletion (c.172-175delAACT; 177delG; p.N58-L59delinsCfsX88) were detected in the other 10 families. CONCLUSIONS Mutations revealed in the present study extend the body of evidence implicating the P2RY5 gene in the pathogenesis of human hereditary hair loss.
Collapse
Affiliation(s)
- M Tariq
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|